Lymphoma Clinical Trial
Official title:
Early Life Exposures in Agriculture
Background:
The Agricultural Health Study (AHS) studied farmers and their spouses in North Carolina and
Iowa. It also included people who worked with pesticides in Iowa. They answered a
questionnaire and gave data about their children born since 1975. Researchers want to link
this data to public data like birth and death certificates. They want to study how early life
exposures to farms are linked to cancer and other bad health outcomes.
Objective:
To study data to find links between early life farm exposure and negative health outcomes.
Eligibility:
There will be no human subjects.
Design:
Researchers will get public data in the two study states. This will come from things like:
Birth certificates
Driver s licenses
Voter registration
Death certificates
Based on these plus the AHS data, they will create a study group. It will be called Early
Life Exposure in Agriculture (ELEA).
Researchers will link ELEA data to cancer data. This will identify prevalence of cancer.
They will study parents answers on the AHS. The topics include farm practices and pesticide
use. They will determine ELEA exposure to pesticides.
Researchers will analyze the cancer and pesticide results and look for links.
There is increasing evidence that early life exposures may influence future health outcomes
although there is a critical need to more fully understand how these may differ from
exposures received later in life. The farm environment includes pesticides that have been
suggested to increase cancer risk in both children and adults. A review of the literature
identified crucial gaps in our knowledge and highlighted the need for accurate exposure
assessment, including separate parental interviews, specific pesticide exposure questions,
and semiquantitative exposure measures that can be used to confirm information obtained
through questionnaires 2. Some studies suggest that the timing of exposure may be
particularly important. For example, in a study of the insecticide DDT and breast cancer,
researchers observed the highest risks among women exposed prior to age 14 compared to later
in life 3. The agricultural environment also includes other exposures such as animals,
allergens, and endotoxins. These exposures may influence immune function, particularly when
exposed at a young age, and subsequently affect later cancer risk.
The Agricultural Health Study (AHS) is a prospective cohort study of farmers and their
spouses residing in North Carolina and Iowa, and commercial pesticide applicators residing in
Iowa. At enrollment (1993-7) women (farmers and spouses of farmers) provided information on
their children born since 1975, including name, gender, SSN and dates of birth. In previous
analyses conducted using Iowa AHS data only for cancer incidence and all-cause mortality in
children under the age of 19, findings suggested increased risks of incident cancer among
these children associated with the use of certain pesticides by their parents. The mortality
analysis focused on fatal injuries sustained, indicative of the dangerous nature of working
on the farm6. In collaboration with researchers at the University of Iowa, we are currently
updating the previous analysis with new cancer incidence information through 2011 and
information provided by the University of Iowa, which has performed a linkage to Iowa birth
certificates to identify additional children born to AHS participants from 1975-2009.
With this proposal, we are proposing to further expand the linkages in Iowa to include
children not previously included, and to link to the North Carolina registries for the first
time to identify additional 2 births, cancer incidence and mortality. This will establish a
unique cohort of agriculturally exposed offspring, with comprehensive information on their
parents farming practices, as well as other information. These data will be used to evaluate
the hypothesis that early life agricultural exposures influence cancer risk. Previous
analyses have only focused on childhood cancers; we will include cancers diagnosed from birth
through adulthood.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00001512 -
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Completed |
NCT01410630 -
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
|
||
Active, not recruiting |
NCT04270266 -
Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT01949883 -
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
|
Phase 1 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Recruiting |
NCT05019976 -
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
|
N/A | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Completed |
NCT04434937 -
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
|
Phase 2 | |
Completed |
NCT01855750 -
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
|
Phase 3 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT00775268 -
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03936465 -
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
|
Phase 1 |